Payment overview · 2025
General Payments
$1,901.14
106 reported records · 26 companies
Healthcare provider profile · identity verified
Timothy J Ryan, D.O.
Allopathic & Osteopathic Physicians|Internal Medicine · MARSHALL, MO · NPI 1790721520
Verified facts
What the public records show
CMS Open Payments records show Timothy J Ryan, D.O. received $1,901.14 in general payments during 2025 across 106 reported records.
AstraZeneca Pharmaceuticals LP accounted for 22.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 40 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Kerendia, Ozempic, Rexulti, Rybelsus, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 46 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 389 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Nexium by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 70 claims for Kerendia by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 327 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 376 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 327 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 113 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 72 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 331 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 376 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $422.64 | 22.2% | 19 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $198.59 | 10.4% | 15 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $157.49 | 8.3% | 12 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $148.87 | 7.8% | 11 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $139.83 | 7.4% | 9 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $105.56 | 5.5% | 5 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $79.43 | 4.2% | 3 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$61.53 | 3.2% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $56.87 | 3.0% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $55.55 | 2.9% | 3 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $51.81 | 2.7% | 3 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $51.55 | 2.7% | 3 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $48.75 | 2.6% | 2 | 2025 |
| Grifols USA, LLC | Unresolved — no canonical attribution shown | $47.32 | 2.5% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $40.56 | 2.1% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $40.13 | 2.1% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $34.70 | 1.8% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $24.38 | 1.3% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $23.70 | 1.2% | 1 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $22.28 | 1.2% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.48 | 0.9% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $17.01 | 0.9% | 1 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $16.90 | 0.9% | 1 | 2025 |
| Vital Connect, Inc | Unresolved — no canonical attribution shown | $15.85 | 0.8% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $14.08 | 0.7% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $8.28 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,901.14 | 106 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FASENRA Normalized: fasenra |
Biological | AstraZeneca Pharmaceuticals LP | $175.67 | 7 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $175.47 | 12 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $149.20 | 11 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $139.83 | 9 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $131.98 | 10 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $129.61 | 5 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $105.56 | 5 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $88.34 | 6 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $81.58 | 5 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $79.43 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $79.27 | 6 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | Amgen Inc., AstraZeneca Pharmaceuticals LP | $69.33 | 3 | 2025 |
Source payment records
|
|||||
| ENDURANT IIS Normalized: endurant iis |
Device | Medtronic, Inc. | $61.53 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $55.55 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $54.08 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $54.08 | 5 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $51.81 | 3 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $48.75 | 2 | 2025 |
Source payment records
|
|||||
| Prolastin-C Liquid Normalized: prolastin c liquid |
Biological | Grifols USA, LLC | $47.32 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $45.13 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $40.56 | 2 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $40.13 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $34.70 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $29.52 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $29.52 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $27.35 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $24.38 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $23.70 | 1 | 2025 |
Source payment records
|
|||||
| TONMYA Normalized: tonmya |
Drug | Tonix Medicines, Inc. | $22.28 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $17.48 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $17.08 | 2 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $17.01 | 1 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $16.90 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $16.89 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $16.89 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $16.89 | 1 | 2025 |
Source payment records
|
|||||
| COBENFY Normalized: cobenfy |
Drug | E.R. Squibb & Sons, L.L.C. | $15.92 | 1 | 2025 |
Source payment records
|
|||||
| VITALPATCH RTM Normalized: vitalpatch rtm |
Device | Vital Connect, Inc | $15.85 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $14.08 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $8.28 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 376 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 327 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 70 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 331 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 91 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
102 | 15 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
46 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
389 | 68 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
70 | 11 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
327 | 52 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
376 | 61 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
327 | 52 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
113 | 15 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
72 | 13 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
331 | 63 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
91 | 15 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
376 | 61 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1148 | 235 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1087 | 196 |
| Omeprazole | Omeprazole | 758 | 156 |
| Potassium Chloride | Potassium Chloride | 718 | 149 |
| Gabapentin | Gabapentin | 673 | 110 |
| Furosemide | Furosemide | 619 | 112 |
| Amlodipine Besylate | Amlodipine Besylate | 618 | 139 |
| Lisinopril | Lisinopril | 538 | 110 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 502 | 91 |
| Sertraline Hcl | Sertraline Hcl | 501 | 92 |
| Metformin Hcl | Metformin Hcl | 474 | 116 |
| Losartan Potassium | Losartan Potassium | 466 | 97 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 432 | 96 |
| Pantoprazole Sodium | Pantoprazole Sodium | 431 | 82 |
| Metoprolol Tartrate | Metoprolol Tartrate | 411 | 99 |
| Farxiga | Dapagliflozin Propanediol | 389 | 68 |
| Oxycodone Hcl | Oxycodone Hcl | 385 | 48 |
| Alprazolam | Alprazolam | 383 | 65 |
| Simvastatin | Simvastatin | 383 | 82 |
| Eliquis | Apixaban | 376 | 61 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 346 | 54 |
| Metoprolol Succinate | Metoprolol Succinate | 343 | 78 |
| Ozempic | Semaglutide | 331 | 63 |
| Jardiance | Empagliflozin | 327 | 52 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 285 | 56 |
| Citalopram Hbr | Citalopram Hydrobromide | 277 | 45 |
| Meloxicam | Meloxicam | 274 | 61 |
| Zolpidem Tartrate | Zolpidem Tartrate | 270 | 38 |
| Ezetimibe | Ezetimibe | 261 | 57 |
| Allopurinol | Allopurinol | 253 | 59 |
| Spironolactone | Spironolactone | 253 | 60 |
| Hydrochlorothiazide | Hydrochlorothiazide | 244 | 54 |
| Tamsulosin Hcl | Tamsulosin Hcl | 238 | 55 |
| Carvedilol | Carvedilol | 223 | 44 |
| Glimepiride | Glimepiride | 219 | 54 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 215 | 46 |
| Duloxetine Hcl | Duloxetine Hcl | 212 | 36 |
| Tizanidine Hcl | Tizanidine Hcl | 209 | 44 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 205 | 40 |
| Fluticasone Propionate | Fluticasone Propionate | 200 | 38 |
| Pregabalin | Pregabalin | 185 | 25 |
| Trazodone Hcl | Trazodone Hcl | 175 | 31 |
| Pravastatin Sodium | Pravastatin Sodium | 171 | 37 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 169 | 36 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 164 | 41 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 160 | 42 |
| Clopidogrel | Clopidogrel Bisulfate | 157 | 32 |
| Fenofibrate | Fenofibrate Nanocrystallized | 156 | 27 |
| Quetiapine Fumarate | Quetiapine Fumarate | 156 | 25 |
| Tramadol Hcl | Tramadol Hcl | 156 | 47 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 153 | 31 |
| Celecoxib | Celecoxib | 151 | 23 |
| Donepezil Hcl | Donepezil Hcl | 150 | 20 |
| Amoxicillin | Amoxicillin | 149 | 100 |
| Xarelto | Rivaroxaban | 136 | 25 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 129 | 24 |
| Memantine Hcl | Memantine Hcl | 129 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 129 | 25 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 129 | 25 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 127 | 30 |
| Fluoxetine Hcl | Fluoxetine Hcl | 125 | 23 |
| Clonazepam | Clonazepam | 120 | 20 |
| Metformin Hcl Er | Metformin Hcl | 115 | 23 |
| Methylprednisolone | Methylprednisolone | 115 | 83 |
| Chlorthalidone | Chlorthalidone | 114 | 28 |
| Lovastatin | Lovastatin | 114 | 27 |
| Montelukast Sodium | Montelukast Sodium | 114 | 19 |
| Mounjaro | Tirzepatide | 113 | 15 |
| Topiramate | Topiramate | 113 | 20 |
| Torsemide | Torsemide | 110 | 28 |
| Paroxetine Hcl | Paroxetine Hcl | 109 | 25 |
| Prednisone | Prednisone | 108 | 33 |
| Azithromycin | Azithromycin | 107 | 62 |
| Tresiba Flextouch U-200 | Insulin Degludec | 104 | 22 |
| Linzess | Linaclotide | 102 | 15 |
| Primidone | Primidone | 102 | 15 |
| Temazepam | Temazepam | 102 | 19 |
| Methocarbamol | Methocarbamol | 99 | 19 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 97 | 30 |
| Levetiracetam | Levetiracetam | 95 | 15 |
| Rybelsus | Semaglutide | 91 | 15 |
| Colestipol Hcl | Colestipol Hcl | 90 | 20 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 90 | 16 |
| Sucralfate | Sucralfate | 83 | 17 |
| Benazepril Hcl | Benazepril Hcl | 76 | 15 |
| Famotidine | Famotidine | 76 | 16 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 76 | 16 |
| Vascepa | Icosapent Ethyl | 76 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 75 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 74 | 49 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 73 | 16 |
| Buspirone Hcl | Buspirone Hcl | 72 | 17 |
| Ondansetron Hcl | Ondansetron Hcl | 72 | 25 |
| Trulicity | Dulaglutide | 72 | 13 |
| Metoclopramide Hcl | Metoclopramide Hcl | 71 | suppressed |
| Kerendia | Finerenone | 70 | 11 |
| Propranolol Hcl | Propranolol Hcl | 67 | 13 |
| Verapamil Er | Verapamil Hcl | 66 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 66 | 15 |
| Amitriptyline Hcl | Amitriptyline Hcl | 65 | 16 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 64 | 12 |
| Estradiol | Estradiol | 63 | 14 |
| Diazepam | Diazepam | 62 | 13 |
| Morphine Sulfate Er | Morphine Sulfate | 62 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 60 | 12 |
| Ibuprofen | Ibuprofen | 58 | 13 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 57 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 57 | 42 |
| Tresiba Flextouch U-100 | Insulin Degludec | 57 | 14 |
| Risperidone | Risperidone | 55 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 54 | 54 |
| Escitalopram Oxalate | Escitalopram Oxalate | 54 | 16 |
| Glipizide | Glipizide | 54 | 11 |
| Glipizide Er | Glipizide | 54 | 11 |
| Methotrexate | Methotrexate Sodium | 54 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 53 | 14 |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 52 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 52 | suppressed |
| Lorazepam | Lorazepam | 52 | 11 |
| Naproxen | Naproxen | 52 | suppressed |
| Baclofen | Baclofen | 51 | suppressed |
| Finasteride | Finasteride | 51 | 13 |
| Mirtazapine | Mirtazapine | 51 | 12 |
| Novolog Flexpen | Insulin Aspart | 51 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 51 | 13 |
| Symbicort | Budesonide/Formoterol Fumarate | 51 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 51 | suppressed |
| Ondansetron Odt | Ondansetron | 50 | 19 |
| Alendronate Sodium | Alendronate Sodium | 48 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 48 | suppressed |
| Aripiprazole | Aripiprazole | 47 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 47 | 43 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 47 | 17 |
| Synthroid | Levothyroxine Sodium | 46 | suppressed |
| Nifedipine Er | Nifedipine | 45 | suppressed |
| Fluconazole | Fluconazole | 44 | 30 |
| Nystatin | Nystatin | 43 | 19 |
| Bupropion Xl | Bupropion Hcl | 42 | 11 |
| Clonidine Hcl | Clonidine Hcl | 42 | 13 |
| Sumatriptan Succinate | Sumatriptan Succinate | 42 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 42 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 41 | 31 |
| Dilt-Xr | Diltiazem Hcl | 41 | suppressed |
| Lamotrigine | Lamotrigine | 41 | suppressed |
| Atenolol | Atenolol | 40 | 13 |
| Levemir Flexpen | Insulin Detemir | 39 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 37 | 15 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 36 | suppressed |
| Pentoxifylline | Pentoxifylline | 36 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 35 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 35 | suppressed |
| Digoxin | Digoxin | 34 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 34 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 34 | suppressed |
| Entresto | Sacubitril/Valsartan | 33 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 33 | suppressed |
| Valsartan | Valsartan | 33 | suppressed |
| Techlite Pen Needle | Pen Needle, Diabetic | 32 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 31 | suppressed |
| Fenofibrate | Fenofibrate | 31 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 31 | 12 |
| Colchicine | Colchicine | 30 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 30 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 29 | suppressed |
| Entacapone | Entacapone | 28 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 28 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 28 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 27 | 14 |
| Dicyclomine Hcl | Dicyclomine Hcl | 27 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 27 | 11 |
| Nebivolol Hcl | Nebivolol Hcl | 27 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 26 | suppressed |
| Cephalexin | Cephalexin | 26 | 12 |
| Diltiazem Hcl | Diltiazem Hcl | 26 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 26 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 26 | suppressed |
| Eszopiclone | Eszopiclone | 26 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 26 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 25 | suppressed |
| Enulose | Lactulose | 25 | suppressed |
| Hydrocortisone | Hydrocortisone | 25 | suppressed |
| Rasagiline Mesylate | Rasagiline Mesylate | 25 | suppressed |
| Cartia Xt | Diltiazem Hcl | 24 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 24 | suppressed |
| Glyburide | Glyburide | 24 | suppressed |
| Lacosamide | Lacosamide | 24 | suppressed |
| Carbamazepine | Carbamazepine | 23 | suppressed |
| Lubiprostone | Lubiprostone | 23 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 23 | suppressed |
| Repatha Sureclick | Evolocumab | 23 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 22 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 22 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 22 | 19 |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 22 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 22 | suppressed |
| Creon | Lipase/Protease/Amylase | 21 | suppressed |
| Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 21 | suppressed |
| Nexium | Esomeprazole Magnesium | 21 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 21 | suppressed |
| Premarin | Estrogens, Conjugated | 21 | suppressed |
| Acyclovir | Acyclovir | 20 | suppressed |
| Januvia | Sitagliptin Phosphate | 20 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Nitroglycerin | Nitroglycerin | 20 | suppressed |
| Olanzapine | Olanzapine | 20 | suppressed |
| Rexulti | Brexpiprazole | 20 | suppressed |
| Cilostazol | Cilostazol | 19 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 19 | 18 |
| Diltiazem 24hr Er | Diltiazem Hcl | 19 | suppressed |
| Lansoprazole | Lansoprazole | 19 | suppressed |
| Fentanyl | Fentanyl | 18 | suppressed |
| Gemtesa | Vibegron | 18 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 18 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 18 | suppressed |
| Humalog | Insulin Lispro | 17 | suppressed |
| Klor-Con M10 | Potassium Chloride | 17 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 16 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 16 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 16 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 16 | 12 |
| Dutasteride | Dutasteride | 16 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 16 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 16 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 16 | suppressed |
| Telmisartan | Telmisartan | 16 | suppressed |
| Zonisamide | Zonisamide | 16 | suppressed |
| Armodafinil | Armodafinil | 15 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 15 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Methimazole | Methimazole | 15 | suppressed |
| Repaglinide | Repaglinide | 15 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 15 | suppressed |
| Butorphanol Tartrate | Butorphanol Tartrate | 14 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Letrozole | Letrozole | 14 | suppressed |
| Novofine Autocover | Pen Needle, Diabetic, Safety | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Repatha Syringe | Evolocumab | 14 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 14 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Vraylar | Cariprazine Hcl | 14 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 13 | suppressed |
| Dextroamphetamine Sulfate Er | Dextroamphetamine Sulfate | 13 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 13 | 13 |
| Icosapent Ethyl | Icosapent Ethyl | 13 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Nitroglycerin Patch | Nitroglycerin | 13 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 13 | suppressed |
| Sotalol | Sotalol Hcl | 13 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 13 | suppressed |
| Trueplus Insulin Syringe | Syringe-Needle,insulin,0.5 Ml | 13 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 12 | suppressed |
| Isoniazid | Isoniazid | 12 | suppressed |
| Modafinil | Modafinil | 12 | suppressed |
| Novolin R Flexpen | Insulin Regular, Human | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Propafenone Hcl | Propafenone Hcl | 12 | suppressed |
| Ramipril | Ramipril | 12 | suppressed |
| Savella | Milnacipran Hcl | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Topiramate Er | Topiramate | 12 | suppressed |
| Ultra-Fine Original Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 11 | suppressed |
| Desonide | Desonide | 11 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 11 | suppressed |
| Levalbuterol Hcl | Levalbuterol Hcl | 11 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 11 | suppressed |
| Prolastin C | Alpha-1-Proteinase Inhibitor | 11 | suppressed |
| Selenium Sulfide | Selenium Sulfide | 11 | suppressed |
| Testosterone | Testosterone | 11 | suppressed |
| Tiagabine Hcl | Tiagabine Hcl | 11 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 11 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 11 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,901.14 · 106 records | AstraZeneca Pharmaceuticals LP | ABRYSVO, AIRSUPRA, Arikayce, BREZTRI, CAPLYTA, COBENFY, COMIRNATY, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, ENDURANT IIS, EVENITY, FASENRA, FREESTYLE LIBRE 3, IBSRELA, JARDIANCE, JOURNAVX, Kerendia, NURTEC ODT, OTEZLA, Ohtuvayre, Ozempic, PREVNAR 20, Prolastin-C Liquid, QULIPTA, REPATHA, REXULTI, Rybelsus, TEZSPIRE, TONMYA, Tymlos, UBRELVY, VAXNEUVANCE, VITALPATCH RTM, VOQUEZNA, VRAYLAR, Wegovy, YUPELRI, ZAVZPRET, ZEPBOUND | 17 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error